Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841679 · ClinicalTrials.gov registry record · Phase 2
Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma, sponsored by Beijing Biostar Pharmaceuticals Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 778
- Enrollment target
- 10
- Study locations
NCT06841679 is a Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma that is actively recruiting participants, run by Beijing Biostar Pharmaceuticals Co.. The registered enrollment target is 778 participants. The trial reports 10 study locations across 2 states.
The verdict
NCT06841679, a Phase 2 study of Gastric or Gastroesophageal Junction Adenocarcinoma, is actively recruiting participants, sponsored by Beijing Biostar Pharmaceuticals Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 778 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Utidelone Capsule
- DRUG Fluoropyrimidine- and Platinum-containing Therapy
Study Locations (10)
Other
- AnYang Tumor Hospital - Anyang
- Sun Yat-sen University Cancer Center - Guangzhou
- Jinan Municipal Central Hospital - Jinan
- Shandong First Medical University Affiliated Tumor Hospital - Jinan
- Liaoning Cancer Hospital - Shenyang
- Shanxi Cancer Hospital - Taiyuan
- Tianjin Medical University Cancer Institute & Hospital - Tianjin
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology - Wuhan
- Henan Cancer Hospital - Zhengzhou
Florida
- Bioresearch Partner - Hialeah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 778 participants |
| Start Date | 2025-08-28 |
| Est. Completion | 2030-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06841679
The ClinicalTrials.gov registry entry for NCT06841679 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 778 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beijing Biostar Pharmaceuticals Co., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric or Gastroesophageal Junction Adenocarcinoma appearing as the primary indexed condition, and to 3 interventions - of which Oxaliplatin is the first listed.
NCT06841679 reports 10 study locations spanning 2 distinct geographic areas - top geographies include Other, Florida.
Frequently Asked Questions
What is clinical trial NCT06841679 about?
NCT06841679 is a clinical study titled "Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma". This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with fluoropyrimidine- and platinum-containing therapy to evaluate the efficacy and safety in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untre...
What is the current status of trial NCT06841679?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 778 participants. The study started on 2025-08-28. Estimated completion is 2030-09-01.
What conditions does trial NCT06841679 study?
This clinical trial studies the following conditions: Gastric or Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT06841679?
The interventions under investigation include: Oxaliplatin (DRUG), Utidelone Capsule (DRUG), Fluoropyrimidine- and Platinum-containing Therapy (DRUG).
Who is sponsoring clinical trial NCT06841679?
This trial is sponsored by Beijing Biostar Pharmaceuticals Co., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06841679 being conducted?
This trial has 10 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric or Gastroesophageal Junction Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
RECRUITING · Phase 1
-
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.